What is Revolade 25mg?
Eltrombopag belongs to the class of medications called thrombopoietin receptor agonists. revolade 25mg is used to increase the number of platelets in the blood for adults with chronic (long-term) immune thrombocytopenia purpura (ITP). … Eltrombopag works by increasing the production of platelets in the body.
Uses of Revolade Tablet
Revolade 25 mg Tablet is used for low platelet count due to ITP or HCV infection. revolade 25 mg uses to treat low platelet count due to chronic immune (idiopathic) thrombocytopenic purpura (ITP) or chronic hepatitis C virus (HCV) infection. It’s also used to treat severe aplastic anemia.
How to use Revolade Tablet
Take this medicine in the dose and duration as advised by your doctor. Swallow it as a whole.eltrombopag how to take Do not chew, crush or break it. Revolade 25 mg Tablet is to be taken empty stomach.
How Revolade Tablet works
Revolade 25 mg Tablet is a thrombopoietin agonist. It works by stimulating the formation of new platelets in the blood. Platelets help to reduce or prevent bleeding.
major & minor eltrombopag side effects following are
- Upper abdominal pain
- Back pain
- Muscle pain
- Common cold
- Tingling sensation in feet or hands
- Abnormal liver function tests
- Cataracts and rash
Expert advice for Revolade Tablet
Take Revolade 25mg Tablet on an empty stomach, either 1 hour before or 2 hours after meals.
Take revolade 25mg dosage at least 2 hours before or 4 hours after eating dairy products and calcium-fortified juices.
What benefits of Revolade have been shown in studies?
For the treatment of chronic ITP in adults, Revolade was compared with placebo (a dummy treatment) in two main studies involving a total of 311 patients who had previously been treated, but the treatments had not worked or the disease had come back.
Revolade was shown to be more effective than placebo: in the first study, 59% of the patients who took Revolade (43 out of 73) achieved a platelet count of at least 50,000 per microlitre (a platelet level considered adequate to prevent the risk of bleeding complications) after six weeks (the main measure of effectiveness), compared with 16% of those who took placebo (6 out of 37). In the second study, patients taking Revolade were around eight times more likely than those taking placebo to reach the target platelet count of between 50,000 and 400,000 per microlitre